Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice
Daniel Reichart(Brigham and Women's Hospital), Christine E. Seidman(Harvard University), Luk H. Vandenberghe(Massachusetts Eye and Ear Infirmary), Jonathan G. Seidman(Harvard University), Sajeev Kohli(Broad Institute), Gregory A. Newby(Broad Institute), Hiroko Wakimoto(Brigham and Women's Hospital), Lukáš Chmátal(Whitehead Institute for Biomedical Research), David R. Liu(Broad Institute), Júlia Daher Carneiro Marsiglia(ID Genomics (United States)), David C. Page(Howard Hughes Medical Institute), Nerea Zabaleta(Massachusetts Eye and Ear Infirmary), David A. Conner(Howard Hughes Medical Institute), Justin J. Curran(Harvard University), Daniel M. DeLaughter(Howard Hughes Medical Institute), Joshua Gorham(Harvard University), Mingyue Lun(Brigham and Women's Hospital), Aditya Raguram(Broad Institute)
Cited by 184
Related Papers
Contemporary Definitions and Classification of the Cardiomyopathies
|Circulation|2006|3.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Circulation|2011|2.1k
CRISPResso2 provides accurate and rapid genome editing sequence analysis
|Nature Biotechnology|2019|1.8k
Cells of the adult human heart
|Nature|2020|1.8k